MedTrace Logo

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-05-25

Study results available
· View outcomes & findings →

Summary

In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical recurrence (BCR) or who have a rising Prostate Specific Antigen (PSA) after treatment of their prostate cancer with surgery or radiation)

Conditions

Interventions

DRUG

Docetaxel

Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles

DRUG

Bevacizumab

Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles

DRUG

ADT

Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)

DRUG

Bicalutamide

Starting on day 84 orally once daily until hormone therapy is completed

Sponsors & Collaborators

Principal Investigators

  • Mary-Ellen Taplin, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2014-09-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658697 on ClinicalTrials.gov